Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CDMO Jan 2022 25.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
4.34000.0000 (0.00%)
As of 09:59AM EST. Market open.
Advertisement
Full screen
Previous Close4.3400
Open4.3400
Bid4.0000
Ask4.3000
Strike25.00
Expire Date2022-01-21
Day's Range4.3400 - 4.3400
Contract RangeN/A
Volume1
Open Interest3
  • InvestorPlace

    7 A-Rated Biotechs to Buy for the Long Run

    While this isn’t the end of giant pharmaceutical companies, there is a new generation of biotechs that have been able to advance rapidly due to the massive advances in computer technology in recent decades. These A-rated biotechs are part of that new generation. The breakthroughs used to build big pharma R&D facilities that we know today are now showing up with smaller biotechs, albeit it with a more focused approach on specific methodologies and diseases. The industry has been slowly transition

  • Zacks

    The Cooper Companies (COO) Q4 Earnings Lag Estimates

    The Cooper Companies (COO) delivered earnings and revenue surprises of -2.67% and 1.52%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021

    TUSTIN, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2022 on December 7, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eas

Advertisement
Advertisement